Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease

Next Previous
Trial Profile

Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms TNT
  • Sponsors Pfizer

    • Most Recent Events

    • 26 Jun 2021 Results of pooled post-hoc analysis of two studies (IDEAL, NCT00159835 and TNT, NCT00327691) were presented at The International Liver Congress 2021.
    • 05 Apr 2018 Results (n=4853) of analysis estimating individual benefit from PCSK9 inhibition in terms of months gained free of stroke or MI in statin treated patients with stable CAD published in the Heart
    • 04 Apr 2018 Results of post-hoc analysis assessing the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial published in the Circulation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top